insulin glargine U-300 Toujeo
Selected indexed studies
- Insulin Glargine U-300 (Toujeo®): A Review. (Home Healthc Now, 2016) [PMID:26925942]
- The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus. (J Am Assoc Nurse Pract, 2016) [PMID:26990724]
- Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL. (Clin Pharmacokinet, 2017) [PMID:27699623]
_Worker-drafted node — pending editorial review._
Connections
insulin glargine U-300 Toujeo is a side effect of
Sources
- Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine. (2025) pubmed
- Insulin Glargine U-300 (Toujeo®): A Review. (2016) pubmed
- The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus. (2016) pubmed
- Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL. (2017) pubmed
- Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis. (2019) pubmed
- The new basal insulin analog glargine U-300 enables flexible injection schedule. (2018) pubmed
- Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus. (2016) pubmed
- Insulin-Induced Acanthosis Nigricans. (2025) pubmed
- Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study. (2024) pubmed
- Endocrinological evaluation of dawn phenomenon in patients with diabetes and comparison of insulin glargine U-100 biosimilar (Insulin Glargine BS Injection "Lilly") and glargine U-300 (Lantus XR): a randomized controlled study. (2023) pubmed